X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs FRESENIUS KABI ONCO. - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH FRESENIUS KABI ONCO. PANACEA BIOTECH/
FRESENIUS KABI ONCO.
 
P/E (TTM) x -16.7 22.1 - View Chart
P/BV x 2.0 3.1 63.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PANACEA BIOTECH   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
FRESENIUS KABI ONCO.
Mar-13
PANACEA BIOTECH/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs149176 84.5%   
Low Rs8279 104.8%   
Sales per share (Unadj.) Rs84.137.7 223.3%  
Earnings per share (Unadj.) Rs-18.35.1 -359.4%  
Cash flow per share (Unadj.) Rs-6.76.7 -99.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.742.5 196.8%  
Shares outstanding (eoy) m61.25158.23 38.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.43.4 40.7%   
Avg P/E ratio x-6.325.0 -25.3%  
P/CF ratio (eoy) x-17.218.9 -91.1%  
Price / Book Value ratio x1.43.0 46.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,07420,135 35.1%   
No. of employees `0002.81.2 238.7%   
Total wages/salary Rs m1,449703 206.1%   
Avg. sales/employee Rs Th1,874.15,176.2 36.2%   
Avg. wages/employee Rs Th527.0610.4 86.3%   
Avg. net profit/employee Rs Th-407.7699.6 -58.3%   
INCOME DATA
Net Sales Rs m5,1545,963 86.4%  
Other income Rs m10018 554.4%   
Total revenues Rs m5,2545,981 87.8%   
Gross profit Rs m-7661,430 -53.6%  
Depreciation Rs m711258 275.7%   
Interest Rs m1,503-26 -5,780.8%   
Profit before tax Rs m-2,8811,216 -236.8%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771-68 -2,600.4%   
Tax Rs m17342 4.9%   
Profit after tax Rs m-1,121806 -139.1%  
Gross profit margin %-14.924.0 -62.0%  
Effective tax rate %-0.628.1 -2.1%   
Net profit margin %-21.813.5 -161.0%  
BALANCE SHEET DATA
Current assets Rs m3,8105,102 74.7%   
Current liabilities Rs m8,3652,385 350.7%   
Net working cap to sales %-88.445.6 -194.0%  
Current ratio x0.52.1 21.3%  
Inventory Days Days156150 103.8%  
Debtors Days Days67113 59.3%  
Net fixed assets Rs m14,4805,148 281.3%   
Share capital Rs m61158 38.7%   
"Free" reserves Rs m9036,556 13.8%   
Net worth Rs m5,1276,732 76.2%   
Long term debt Rs m5,832952 612.4%   
Total assets Rs m19,43310,388 187.1%  
Interest coverage x-0.9-45.8 2.0%   
Debt to equity ratio x1.10.1 804.1%  
Sales to assets ratio x0.30.6 46.2%   
Return on assets %2.07.5 26.2%  
Return on equity %-21.912.0 -182.7%  
Return on capital %3.614.6 24.9%  
Exports to sales %24.574.5 32.9%   
Imports to sales %10.224.8 41.1%   
Exports (fob) Rs m1,2644,441 28.5%   
Imports (cif) Rs m5251,477 35.5%   
Fx inflow Rs m1,5395,298 29.1%   
Fx outflow Rs m9421,772 53.2%   
Net fx Rs m5973,525 16.9%   
CASH FLOW
From Operations Rs m5991,274 47.0%  
From Investments Rs m-438-1,204 36.4%  
From Financial Activity Rs m-303-196 154.3%  
Net Cashflow Rs m-141-126 111.9%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 0.6 0.3 200.0%  
FIIs % 1.3 9.6 13.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 9.1 259.3%  
Shareholders   10,259 42,599 24.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  WOCKHARDT LTD.  NOVARTIS  DR. DATSONS LABS  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Nov 14, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - CIPLA COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS